SRT1720 HCl

Catalog No.S1129

SRT1720 HCl Chemical Structure

Molecular Weight(MW): 506.02

SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.

Size Price Stock Quantity  
In DMSO USD 238 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • EMBO J 2013 32, 791-804. SRT1720 HCl purchased from Selleck.

    Sirt1 deacetylase activity is essential for IRF9-mediated ischemic injury. The effects of SRT1720 on Sirt1 deacetylase activity in IRF9-KO and IRF9-TG mice, respectively. *p < 0.05 versus DMSO controls. n = 5.

    J Neurosci 2014 34(36), 11897-912. SRT1720 HCl purchased from Selleck.

  • PAI-1 expression in HUVECs treated with drugs as indicated.(D) senescent HUVECs were treated with SRT1720, culturing for 24, 48 hours. PAI-1 mRNA and protein (E) levels were analyzed using real-time RT–PCR and Western blotting, respectively. The RNA and protein levels were normalized to the internal control β-actin. Data are presented as the mean±SEM of three independent experiments. *P < 0.05 vs. corresponding control. **P < 0.01 vs. corresponding control ***P < 0.001 vs. corresponding control.

    Aging Cell 2014 13(5), 890-9. SRT1720 HCl purchased from Selleck.

    C2C12 myoblasts were transfected with si-CON and si-NDUFV1 for 24 h and then further differentiated into myotubes for 4 days in the absence or presence of pyruvate (25 mM), SRT1720 (2 uM), or resveratrol (Resv; 25 uM). Myogenesis was monitored using MyHC immunofluorescence and DAPI.

    J Biol Chem 2014 289(29), 20012-25. SRT1720 HCl purchased from Selleck.

  • J Biol Chem 2012 287, 19304-19314. SRT1720 HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Biological Activity

Description SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  MlzySpVv[3Srb36gRZN{[Xl? NFXXcpA1yqEQvF2= MVuzNOKhdWmw NGDMOpNFVVOR NITDeWNqdmS3Y3XzJIFkfXSnIGPJVnQyKGGldHn2ZZRqd28EoB?= NXXXRWlvOjZ{NUSxNFQ>
MC3T3-E1 MoLFSpVv[3Srb36gRZN{[Xl? M{W1dVExKML3TdMg MmnpNUBp NUjMN4MyemWmdXPld{B1cGViVFfGMe6zNXO2aX31cIF1\WRiVlXHSkBz\WynYYPlJIlvKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> MlL3NlYyOzZ7N{i=
MC3T3-E1 NYPC[4xuTnWwY4Tpc44hSXO|YYm= NX7hSpN[OTBiwsXNxsA> M3vzTlEzKGh? NX\QOHNIemWmdXPld{B1cGViVlXHSkBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IIP0bY12dGG2ZXSgZpkhXEeILd8y NVjvbnhMOjZzM{[5O|g>
MC3T3-E1 MXXGeY5kfGmxbjDBd5NigQ>? MmriNlAh|ryP MmT2NUBp MYrzeZBxemW|c3XzJJRp\SCWR1[t{tIucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDR2L4C0NkBOSVBia3nuZZNmKG:{IGPBVGswUk6N M1rscVI3OTN4OUe4
WE-68 M1T2TGFxd3C2b4Ppd{BCe3OjeR?= NGLCVVUxNTJ2IN88US=> NXvnUFZJOjRiaB?= NX\YRVZZcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? MViyOlA2PThyNR?=
SK-ES-1 NY\CfFNESXCxcITvd4l{KEG|c3H5 NFiyS40xNTFyIN88US=> M{jSUlI1KGh? MnzHbY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> MYmyOlA2PThyNR?=
SK-N-MC  NXntRpJISXCxcITvd4l{KEG|c3H5 MWiwMVIvPSEQvF2= MV2yOEBp NIDkd3hqdmS3Y3XzJINmdGxiZHXheIghcW5iZH;z[UBl\XCnbnTlcpRtgQ>? M1jqTlI3ODV3OEC1
WE-68 M1HOcWZ2dmO2aX;uJGF{e2G7 Ml6zNlAh|ryP NWPOVnIyOC1{NDDo M{G4VYFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? MWqyOlA2PThyNR?=
SK-ES-1 NVXneGpTTnWwY4Tpc44hSXO|YYm= MnHINVAh|ryP MV2wMVI1KGh? NHrWRWdi[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? M4DXVVI3ODV3OEC1
SK-N-MC  NVrwbXhNTnWwY4Tpc44hSXO|YYm= M1PuV|Mh|ryP MVOwMVI1KGh? NU\uZlJX[WO2aY\heIV{KGOjc4Dhd4UhOy95 MmnqNlYxPTV6MEW=
NRK-49F MWfGeY5kfGmxbjDBd5NigQ>? MUCw5qCUOsLizszN MXSzOkBp NVv2c3lPcW6lcnXhd4V{KGW6cILld5Nqd25ib3[g{tEuW02DIHHu[EBncWK{b37lZ5RqdiCmb4PlJIRmeGWwZHXueIx6 M3ixUlI3ODJ{MECz
NRK-49F NFPkV|FHfW6ldHnvckBCe3OjeR?= MWOw5qCUOsLizszN NUS5S481OzZiaB?= MkPF[Y5p[W6lZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJiYX7kJHBFT0[UzsNCpC=> NVHaTpVCOjZyMkKwNFM>
NRK-49F Mk\uSpVv[3Srb36gRZN{[Xl? NIrhU40x6oDVMtMg{txO M1K1VVM3KGh? NU\pW4ZP\W6qYX7j[ZMhW1SDVEOgdIhwe3Cqb4L5cIF1cW:w MlvHNlYxOjJyMEO=
RAW264.7 MkXlSpVv[3Srb36gRZN{[Xl? NFvXWXQyKM7:TR?= M37a[|YhcA>? NYrDUndEfXC{ZXf1cIF1\XNidHjlJJJm\HWlZXSgV2lTXDFicILveIVqdiCxcjDtVm5CKGyndnXsd{BjgSCqaXfoJIdtfWOxc3W= MVSyOVc6Ozl7NR?=
MCF10A MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:3U4ZPOC1{MDFOwG0> NV\IUoUzOjRiaB?= NYHKR3M4emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M3TibVI2PDFzM{W2
MCF-7 M2q0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Tk[VAuOjBizszN MWKyOEBp MmexdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MnL6NlU1OTF|NU[=
T47D M1fUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOwMVIxKM7:TR?= NFfZbYszPCCq NWDjWo1xemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MXmyOVQyOTN3Nh?=
SKBR3 M1;sVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiwMVIxKM7:TR?= NHnSVmozPCCq MUDy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MljLNlU1OTF|NU[=
MDA-MB-231 NF2zb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjmOHIxNTJyIN88US=> NFzGO3kzPCCq MoHVdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NHHrUXYzPTRzMUO1Oi=>
SUM149 NXraNIlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWzV4oxNTJyIN88US=> MXiyOEBp M1exe5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NYHRWG9sOjV2MUGzOVY>
HS578T NX3OS29ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjFZmUxNTJyIN88US=> MmPJNlQhcA>? NXu3W|Z6emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYTPfnhUOjV2MUGzOVY>
BT20 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmwMVIxKM7:TR?= NIDSVpgzPCCq NWXSPYpLemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MWmyOVQyOTN3Nh?=
A459 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMVIxKM7:TR?= NX3IZ|hoOjRiaB?= Mk\zdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MoH0NlU1OTF|NU[=
HCT116 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnuNE0zOCEQvF2= Mom1NlQhcA>? NFPiNpdz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MUeyOVQyOTN3Nh?=
Neu NF3MVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVGwMVIxKM7:TR?= NEPPZYczPCCq NHLYfGpz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NIXWToQzPTRzMUO1Oi=>
MDA-MB-231 MoLMSpVv[3Srb36gRZN{[Xl? NF\GfIw2KM7:TR?= NUC5XpNKQCCq MX;pcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCjY3nkbYMhfmW|aXP1cIFzKG:{Z3Hu[Yxt\XN? NXrxco5TOjV2MUGzOVY>
MDA-MB-231 NXLiTVdDTnWwY4Tpc44hSXO|YYm= NFzoWGY2KM7:TR?= MVGxOkBp M2Tp[olv\HWlZYOgcJl{d3OxbXHsJI1mdWK{YX7lJJBmem2nYXLpcIl7[XSrb36= MYqyOVQyOTN3Nh?=
MC3T3-E1 NFjpXI5HfW6ldHnvckBCe3OjeR?= NGXY[nYyOCEQvF2= MWW2NEBucW8EoB?= MX7zeZBxemW|c3XzJJRp\SCIR1[tNk1{fGmvdXzheIVlKG:|dHXvdJJwfGWpZYLpckBz\WynYYPl Mmn3NlUzQTByOUW=
MC3T3-E1 NFLEbXpHfW6ldHnvckBCe3OjeR?= MkLQNVAh|ryP MYq2NEBucW8EoB?= NH;PdJhifHSnboXheIV{KHSqZTDGS2YuOi2rbnT1Z4VlKG:|dHXvdJJwfGWpZYLpckBuWk6DIHX4dJJme3Orb36= MWCyOVI6ODB7NR?=
MC3T3-E1 M{XPPGZ2dmO2aX;uJGF{e2G7 NFr5To0yOCEQvF2= MkTTOlAhdWmwwrC= M4TSV4F1fGWwdXH0[ZMhfGinIF\HSk0zNWmwZIXj[YQhd3O2ZX;wdo91\WencnnuJI1TVkFiZYjwdoV{e2mxbh?= MWOyOVI6ODB7NR?=
MC3T3-E1 MWnGeY5kfGmxbjDBd5NigQ>? NXH4Um9IOTBizszN MlG1OlAhdWmwwrC= MYfzeZBxemW|c3XzJJRp\SCETWCtOE1{fGmvdXzheIVlKF[HR1[gdoVt\WG|ZR?= NVHTUmxbOjR2M{W0OFQ>
MC3T3-E1 NVnFdnBxTnWwY4Tpc44hSXO|YYm= NYS5PWt1OTBizszN MVO2NEBucW8EoB?= MV3zeZBxemW|c3XzJJRp\SCSR1[y{tEue3SrbYXsZZRm\CCRUFegdoVt\WG|ZR?= MVSyOFM{OzN|Nh?=
MC3T3-E1 NHXo[HVHfW6ldHnvckBCe3OjeR?= M3;EUlExKM7:TR?= NUPMZYxKPjBibXnuxsA> NWnGO|RRemWmdXPld{B1cGViUFfGNu6yNXO2aX31cIF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIIC0OE9xPDJiTVHQJItqdmG|ZR?= MnzpNlQ{OzN|M{[=
MC3T3-E1 M3qwZ2Z2dmO2aX;uJGF{e2G7 MYexNEDPxE1? Mnj6OlAhdWmwwrC= M1jQSoF1fGWwdXH0[ZMhfGinIGDHSlLPuS2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCkb4ToJG1GUzFxMjDhcoQhWmGoLUG= MV:yOFM{OzN|Nh?=
RPE NXOyPIFsS2WubDDWbYFjcWyrdImgRZN{[Xl? NWjHOnI3PSEEtV2= MljXNUBp NGLEVIlifHSnboXheIV{KE:DzsKtbY5lfWOnZDDk[YNz\WG|ZTDv[kBk\WyuII\pZYJqdGm2eR?= M3XsUlI1ODN4OUO4
9607 MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2Xj[lEh|ryP M1H4NFM3KGh? MmHsbY5kemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkd22yYYLl[EB4cXSqIH3lcIF1d26rbjDhcI9v\Q>? NH[z[lAzOzd{Nkm0PS=>
9607 NIXJdIlHfW6ldHnvckBCe3OjeR?= NUnmWGFEOSEQvF2= NH\6Xm8{PiCq MmTYbY5kemWjc3XzJHNKWlRzIHHu[EBl\WO{ZXHz[YQh[WOndInsZZRm\C2yNUOg[ZhxemW|c3nvci=> MYSyN|czPjl2OR?=
RPMI.8226 MmrYR4VtdCCYaXHibYxqfHliQYPzZZk> NXzxbllnPy9zMDFOwG0> MXWyOEBp MkDC[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MmXGNlE6PTB5Mki=
U266 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXnLN5pJPy9zMDFOwG0> NWXYXWlTOjRiaB?= NVrrRoZN\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 M4HDcVIyQTVyN{K4
MM.1S MoGxR4VtdCCYaXHibYxqfHliQYPzZZk> MV23M|ExKM7:TR?= M2DCelI1KGh? MWHk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MkWxNlE6PTB5Mki=
KMS12 NFj6WHBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{O4e|cwOTBizszN MnPSNlQhcA>? M1;RW4Rm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NYfUW|dpOjF7NUC3Nlg>
LR5 NYXaXHBIS2WubDDWbYFjcWyrdImgRZN{[Xl? NGXrZ5Y4NzFyIN88US=> NHzoc3gzPCCq M3q1S4Rm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> M4XFWlIyQTVyN{K4
MM.1R M2m5OmNmdGxiVnnhZoltcXS7IFHzd4F6 MV[3M|ExKM7:TR?= NWnZ[294OjRiaB?= MUTk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NU\iXpdzOjF7NUC3Nlg>
Ina6 MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH\zXXQ4NzFyIN88US=> NXroZYhsOjRiaB?= NWLXPZBN\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MV6yNVk2ODd{OB?=
RPMI-8226 NHf2dnJCeG:ydH;zbZMhSXO|YYm= NHrwNHE4NzFyIN88US=> MYeyOEBp NXmxVWcycW6mdXPld{BiKHOrZ37p[olk[W62IHnuZ5Jm[XOnIHnuJJRp\SCDbn7lfIlvKFZtL2DJ5qiTyqCjcH;weI9{cXN? MYKyNVk2ODd{OB?=
MM.1R  NWfIZlhUSXCxcITvd4l{KEG|c3H5 MlG1O{8yOCEQvF2= NFqycHozPCCq MYLpcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5idHjlJGFvdmW6aX6gWkswWEokiKNCpIFxd3C2b4Ppdy=> MmjoNlE6PTB5Mki=
H411EC3 Ml;5SpVv[3Srb36gRZN{[Xl? MUm1NE8yODBibl2= MUG2JIg> MVzpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> M1X2UlIyOjF{MEm2
hepatocytes M3rROmZ2dmO2aX;uJGF{e2G7 M3mxZ|ExKG6P MX[2JIg> NHTSWlBqdmO{ZXHz[ZMhW0mUVEGgZYN1cX[rdImgbY4hfGinIIDy[ZNmdmOnIH;mJHRUSSxiUFXQR2sh[WO2aY\peJktKG2UTlGgcIV3\Wy|IH;mJHBkczFiYX7kJHBo[zIQsTygZY5lKGWuZY\heIlv\yCpbIXjc5NmKHC{b3T1Z5Rqd25? MVeyNVIyOjB7Nh?=
hepatocytes MX7GeY5kfGmxbjDBd5NigQ>? MXexNEBvVQ>? M1;qblYhcA>? NVTPNWttcW6lcnXhd4V{KEivZ3PyxsBidmUEoFHjZ:Kh\2WwZTDlfJBz\XO|aX;u Mn\NNlEzOTJyOU[=

... Click to View More Cell Line Experimental Data

In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol

Kinase Assay:[1]
+ Expand

SIRT1 fluorescence polarization assay:

In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.
Cell Research:[2]
+ Expand
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Formulation: 20% PEG400/0.5% Tween80/79.5% deionized water
  • Dosages: 200 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (75.09 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% Propylene glycol
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we prepare Srt1720 for in vivo mouse studies?

  • Answer:

    SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

Sirtuin Signaling Pathway Map

Related Sirtuin Products

Tags: buy SRT1720 HCl | SRT1720 HCl supplier | purchase SRT1720 HCl | SRT1720 HCl cost | SRT1720 HCl manufacturer | order SRT1720 HCl | SRT1720 HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID